Verhelst Steven H L
Department of Cellular and Molecular Medicine, KU Leuven - University of Leuven, Belgium.
AG Chemical Proteomics, Leibniz Institute for Analytical Sciences ISAS, Dortmund, Germany.
FEBS J. 2017 May;284(10):1489-1502. doi: 10.1111/febs.13979. Epub 2017 Jan 6.
Proteases are considered attractive drug targets. Various drugs targeting classical, soluble proteases have been approved for treatment of human disease. Intramembrane proteases (IMPs) are a more recently discovered group of proteolytic enzymes. They are embedded in lipid bilayers and their active sites are located in the plane of a membrane. All four mechanistic families of IMPs have been linked to disease, but currently, no drugs against IMPs have entered the market. In this review, I will outline the function of IMPs with a focus on the ones involved in human disease, which includes Alzheimer's disease, cancer, and infectious diseases by microorganisms. Inhibitors of IMPs are known for all mechanistic classes, but are not yet very potent or selective - aside from those targeting γ-secretase. I will here describe the different features of IMP inhibitors and discuss a list of issues that need attention in the near future in order to improve the drug development for IMPs.
蛋白酶被认为是有吸引力的药物靶点。多种针对经典可溶性蛋白酶的药物已获批用于治疗人类疾病。膜内蛋白酶(IMPs)是一组较新发现的蛋白水解酶。它们嵌入脂质双层中,其活性位点位于膜平面内。所有四个机制家族的膜内蛋白酶都与疾病有关,但目前尚无针对膜内蛋白酶的药物进入市场。在这篇综述中,我将概述膜内蛋白酶的功能,重点关注那些与人类疾病相关的膜内蛋白酶,这些疾病包括阿尔茨海默病、癌症和微生物感染性疾病。已知所有机制类别的膜内蛋白酶抑制剂,但除了那些靶向γ-分泌酶的抑制剂外,目前还不是很有效或具有选择性。我将在这里描述膜内蛋白酶抑制剂的不同特点,并讨论一系列在不久的将来需要关注的问题,以便改进针对膜内蛋白酶的药物研发。